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Abstracts: This study aimed to identify expression profiles of Yes-associated protein (YAP) and its phosphorylated 
form (pYAP) in phyllodes tumor (PT) of human breast and verify the clinical implications. We selected PTs from the 
pathologic archive and reviewed the histologic features (141 benign, 27 borderline, and 15 malignant). We made 
tissue microarray (TMA) block from the formalin-fixed paraffin-embedded (FFPE) tissue corresponding to the repre-
sentative section. Using TMA block, we performed immunohistochemical staining of YAP and pYAP. In the stromal 
component, expressions of YAP and pYAP were increased in borderline/malignant PT with comparison of benign PT 
(P = 0.002, and P < 0.001, respectively). In the epithelial component, cytoplasmic expression of YAP was highest 
in borderline PT (P = 0.001). Stromal YAP expression (P < 0.001) and stromal pYAP expression (P = 0.042) were 
associated with shorter disease-free survival (DFS) and stromal pYAP expression (P = 0.001) was associated with 
shorter overall survival (OS) in univariate Cox analysis. In multivariate Cox analysis, stromal YAP expression was an 
independent prognostic factor associated with shorter DFS (Hazard ration: 3.206, 95% CI: 1.000-10.27, P = 0.050). 
In conclusion, expression level of YAP in stromal component was increased along with histologic grade of PT and YAP 
expression in PT was related to tumor progression and poor prognosis.
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Introduction
Phyllodes tumor (PT) is less common consisting 
0.3-1.5% of tumors of breast origin. PT, one of 
fibroepithelial tumors, is composed of stromal 
component and epithelial component, howev-
er, there is no simple criterion to distinguish PT 
from other fibroepithelial tumors such as fibro-
adenoma because fibroepithelial tumors share 
much of histologic features and PT could show 
a wide spectrum of histologic features resulting 
in tumor heterogeneity [1, 2]. According to WHO 
classification, the 3 tiered grading subtypes, 
such as benign, borderline, and malignant, are 
recommended for diagnosis of PT and deter-
mined by histologic features of stromal compo-
nent reflecting tumor behavior [2, 3]. Therefore, 
it is needed to fine adjunctive markers which 
help to ensure the histologic grades and pre-
dict a more precise patient’s prognosis of PT. 
Yes-associated protein (YAP) is a transcription 
coactivator and it is believed that YAP could act 
as an oncogene in the nucleus although phos-
phorylated YAP (pYAP) is sequestrated in the 
cytoplasm [4, 5]. In several solid organs includ-
ing lung, skin, prostate, ovary, liver, and breast, 
YAP overexpression has been reported in the 
tumor and solid tumors with YAP overexpres-
sion was related to poor prognosis [6-14]. 
However, expression profiles of YAP in PT and 
its clinical implications have not been fully 
studied. 
On studying PT in this report, we aimed to verify 
the expression status of YAP and pYAP in stro-
mal component of tumor according to the histo-
logic grades. To detail, we assessed the expres-
sion profiles of YAP and pYAP in epithelial com-
ponent and stromal component of PT, respec-
tively, and compared differences of YAP and 
pYAP expression status between these two cel-
lular components. Finally, we identified the rela-
tion of YAP expression in each cellular compo-
nents and survival of PT patients.
Materials and methods
Patient selection
We retrospectively reviewed PTs from the patho-
logic archive of the department of pathology of 
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Severance hospital. They had been surgically 
excised and diagnosed from 2000 to 2010. 
The study was approved by The Institutional 
Review Board of Yonsei University Severance 
Hospital. All tissues were fixed in 10% buffered 
formalin and embedded in paraffin. All archival 
hematoxylin and eosin (H&E)-stained slides for 
each case were reviewed by 2 pathologists (JS 
Koo and W Jung). We assessed histologic grade 
of PT according to the recommended criteria by 
WHO classification [2]. Histologic features of PT 
were reviewed by three breast pathologists. 
Histologic parameters such as stromal cellular-
ity, stromal atypia, stromal mitosis, stromal 
overgrowth, and tumor margin were evaluated 
on H&E-stained slides. Included clinical param-
eters were patient age at initial diagnosis, 
tumor size, local recurrence, distant metasta-
sis, methods of surgical resection, and postop-
erative radiation therapy. 
Tissue microarray
On H&E stained slides of tumors, a representa-
tive area was selected and the corresponding 
spot was marked on the surface of the paraffin 
block. Using a punch machine, the selected 
area was punched out and a 3-mm tissue core 
was placed into a 6 × 5 recipient block. Two tis-
sue cores were extracted to minimize extrac-
tion bias. Each tissue core was assigned a 
unique tissue microarray location number that 
was linked to a database containing other clini-
copathologic data. 
Immunohistochemistry
We used formalin-fixed, paraffin-embedded 
(FFPE) tissue sections for immunohistochemi-
cal staining. Briefly, 5-μm-thick sections were 
obtained with a microtome, transferred into 
Table 1. Clincopathologic characteristics of patients with phyllodes tumor
Parameters Number of Patients  
n = 183 (%)
PT, Benign  
n = 141 (%)
PT, Borderline  
n = 27 (%)
PT, Malignant  
n = 15 (%)
P-value
Age (y, mean ± SD) 40.3 ± 12.2 39.1 ± 11.9 42.7 ± 11.9 47.6 ± 13.4 0.019
Tumor size (cm, mean ± SD) 4.0 ± 2.6 3.7 ± 2.2 4.3 ± 2.5 6.2 ± 4.3 0.001
Stromal cellularity < 0.001
    Mild 111 (60.7) 110 (78.0) 1 (3.7) 0 (0.0)
    Moderate 61 (33.3) 31 (22.0) 23 (85.2) 7 (46.7)
    Marked 11 (6.0) 0 (0.0) 3 (11.1) 8 (53.3)
Stromal atypia < 0.001
    Mild 145 (79.2) 139 (98.6) 6 (22.2) 0 (0.0)
    Moderate 29 (15.8) 2 (1.4) 19 (70.4) 8 (53.3)
    Marked 9 (4.9) 0 (0.0) 2 (7.4) 7 (46.7)
Stromal mitosis < 0.001
    0-4/10 HPFs 143 (78.1) 141 (100.0) 2 (7.4) 0 (0.0)
    5-9/10 HPFs 30 (16.4) 0 (0.0) 25 (92.6) 5 (33.3)
    ≥ 10/10 HPFs 10 (5.5) 0 (0.0) 0 (0.0) 10 (66.7)
Stromal overgrowth < 0.001
    Absent 168 (91.8) 141 (100.0) 25 (92.6) 2 (13.3)
    Present 15 (8.2) 0 (0.0) 2 (7.4) 13 (86.7)
Tumor margin < 0.001
    Circumscribed 165 (90.2) 139 (98.6) 20 (74.1) 6 (40.0)
    Infiltrative 18 (9.8) 2 (1.4) 7 (25.9) 9 (60.0)
Tumor local recurrence 17 (9.3) 5 (3.5) 5 (18.5) 7 (46.7) < 0.001
Distance metastasis 7 (3.8) 0 (0.0) 0 (0.0) 7 (46.7) < 0.001
Surgical treatment < 0.001
    Lumpectomy 139 (76.0) 124 (87.9) 14 (51.9) 1 (6.7)
    Partial mastectomy 33 (18.0) 12 (8.5) 12 (44.4) 9 (60.0)
    Total mastectomy 11 (6.0) 5 (3.5) 1 (3.7) 5 (33.3)
Radiation therapy < 0.001
    No 176 (96.2) 140 (99.3) 25 (92.6) 11 (73.3)
    Yes 7 (3.8) 1 (0.7) 2 (7.4) 4 (26.7)
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adhesive slides, and dried at 62°C for 30 min-
utes. After incubation with primary antibodies 
for YAP (1: 100, Santa cruz biotechnology), 
phosphorylated YAP (ser127) (1: 100, Cell sig-
naling), immunodetection was performed with 
biotinylated antimouse immunoglobulin, fol-
lowed by peroxidase-labeled streptavidin using 
a labeled streptavidin biotin kit with 3,3’-diami-
nobenzidine chromogen as substrate. The pri-
mary antibody incubation step was omitted in 
the negative control. Positive control tissue 
was used as manufacturer’s recommendation. 
Slides were counterstained with Harris 
hematoxylin.
Interpretation of immunohistochemical stain-
ing
We assessed YAP and pYAP expression in tumor 
cells of each epithelial and stromal component. 
In detail, YAP and pYAP expression in the nucle-
us and the cytoplasm of each tumor cells were 
also evaluated. Immunostaining result was 
graded 0 (negative), 1 (weak), 2 (moderate), or 
3 (strong). Because normal ductal cells also 
occasionally demonstrated weak positivity of 
YAP and pYAP, we estimated positive criteria as 
over grade 2+ tumor cells were identified in 
more than 10% of tumor area. 
Statistical analysis
Data were analyzed using SPSS for Windows, 
Ver-sion 12.0 (SPSS Inc., Chicago, IL, USA). For 
determination of statistical significance, 
Student’s t and Fisher’s exact tests were used 
for continuous and categorical variables, res- 
pectively. Sta-tistical significance was when P < 
0.05. Kaplan-Meier survival curves and log-
rank statistics were employed to evaluate time 
to tumor recurrence and overall survival. 
Multivariate regression analysis was performed 
using Cox proportional hazards model.
Results
Patients’ basic characteristics and pathologic 
features of PT
183 cases of PT were included in this study. We 
summarized clinical characteristics of PT 
patients and reviewed histologic features 
(Table 1). The worse tumor grade, the more age 
at diagnosis (P = 0.019) and the larger tumor 
size (P = 0.001). Local recurrence and distant 
metastasis were more frequently identified in 
malignant PT (P < 0.001). 33.3% and 26.7% of 
malignant PT patients received total mastecto-
my and radiation therapy, respectively, which 
were much higher incidence rather than 
patients of benign or borderline PTs (P < 0.001). 
As defined, stromal cellularity, stromal atypia, 
stromal mitosis, and stromal over growth was 
marked as the histologic grade of PT increased 
(P < 0.001). Infiltrative tumor margin rather 
than circumscribed margin was also most fre-
quently identified in malignant PT (P < 0.001).
Table 2. Expression of YAP and pYAP according to phyllodes tumor grade
Parameters Number of Patients
n = 183 (%)
PT, Benign
n = 141 (%)
PT, Borderline
n = 27 (%)
PT, Malignant
n = 15 (%)
P-value
YAP (E-Nu)* 0.784
    Negative 173 (98.9) 139 (98.6) 26 (100.0) 8 (100.0)
    Positive 2 (1.1) 2 (1.4) 0 (0.0) 0 (0.0)
YAP (E-Cy)* 0.001
    Negative 164 (93.7) 136 (96.5) 20 (76.9) 8 (100.0)
    Positive 11 (6.3) 5 (3.5) 6 (23.1) 0 (0.0)
YAP (S) 0.002
    Negative 165 (90.2) 133 (94.3) 20 (74.1) 12 (80.0)
    Positive 18 (9.8) 8 (5.7) 7 (25.9) 3 (20.0)
pYAP (E)* 0.194
    Negative 82 (46.9) 66 (46.8) 10 (38.5) 6 (75.0)
    Positive 93 (53.1) 75 (53.2) 16 (61.5) 2 (25.0)
pYAP (S) < 0.001
    Negative 158 (86.3) 132 (93.6) 19 (70.4) 7 (46.7)
    Positive 25 (13.7) 9 (6.4) 8 (29.6) 8 (53.3)
Abbreviations: PT, Phyllodes Tumor; E, epithelial component; S, stromal component; Nu, nuclear; Cy, cytoplasmic. *8 cases 
without an epithelial component were excluded.
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Expression of YAP and pYAP according to the 
histologic grade of phyllodes tumor
We performed immunohistochemical staining 
of YAP and pYAP on PTs with various histologic 
grades and then assessed their expression 
profiles by epithelial and stromal components 
(Table 2 and Figure 1). Eight out of 183 PTs 
were excluded because we could not detect 
epithelial component in the TMA cores made 
from these eight cases. Although nuclear 
expression of YAP in epithelial component were 
rarely identified, cytoplasmic YAP expression 
was more frequently identified in benign and 
borderline tumors rather than in malignant PT 
(P = 0.001). pYAP expression of epithelial com-
ponent was also increased in benign and bor-
derline PTs rather than in malignant PT, but it 
was not statistically significant (P = 0.194). 
Therefore, we suggested that YAP might not 
play an important role as a transcription coacti-
vator in the nucleus of epithelial component of 
PT because YAP protein was predominantly 
located in the cytoplasm. Next, we analyzed the 
expression profiles of YAP and pYAP in stromal 
component. Interestingly, nuclear YAP expres-
sion was more frequently identified in border-
line and malignant PTs (P = 0.002). pYAP 
expression was also increased according to his-
tologic grade: the worse histologic grade of PT, 
the more frequently expressed pYAP (P < 
0.001). These result indicated that YAP expres-
sion was generally increased in stromal cells of 
high grade PTs.
Correlation between YAP and pYAP with clinico-
pathologic parameters
We investigated the associations of YAP and 
pYAP expressions of PTs and their clinicopatho-
logic parameters (Figure 2). As a result, 
increased levels of YAP and pYAP expressions 
were associated with marked stromal cellulari-
ty, stromal atypia, increased number of stromal 
mitosis, and stromal overgrowth (P < 0.05). 
pYAP expression in stromal component was 
more frequently associated with infiltrative 
tumor margin rather than circumbstrcibed 
tumor margin (P = 0.005). On the other hand, 
Figure 1. Expression for YAP and pYAP according to the histologic grade of phyllodes tumor. YAP and pYAP expres-
sions in stromal component were identified more frequently in borderline and malignant PTs.
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Table 3. The impact of YAP and pYAP expression on prognosis by univariate analysis using the log-rank 
test
Parameters Total number/recurrence/death
Disease-free survival Overall survival
Median survival (95% CI) 
months p-value
Median survival (95% CI)  
months p-value
YAP(E-Nu)* n/a n/a
    Negative 173/13/2 n/a n/a
    Positive 2/0/0 n/a n/a
YAP (E-Cy)* 0.169 n/a
    Negative 164/11/2 170 (163-177) n/a
    Positive 11/2/0 99 (75-122) n/a
YAP (S) < 0.001 0.051
    Negative 165/11/5 170 (163-177) 177 (172-182)
    Positive 18/6/2 80 (56-105) 106 (90-121)
pYAP (E)* 0.532 0.933
    Negative 82/5/1 168 (159-177) 176 (172-180)
    Positive 93/8/1 166 (156-177) 180 (175-185)
pYAP (S) 0.042 0.001
    Negative 158/12/3 169 (161-176) 179 (176-183)
    Positive 25/5/4 120 (97-143) 126 (105-147)
Abbreviations: E, epithelial component; S, stromal component; Nu, nuclear; Cy, cytoplasmic. *8 Cases without an epithelial 
component were excluded.
Figure 2. Correlation between clinicopathologic factors and YAP/pYAP expression in phyllodes tumor.
YAP in phyllodes tumor
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Figure 3. Disease-free survival and 
overall survival according to the ex-
pression of YAP in phyllodes tumor 
(A-D) and borderline PT (E).
Table 4. Multivariate analysis in patients with phyllodes tumors
Factor
Disease-free survival Overall survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Stromal cellularity 0.931 n/a
    Mild vs. moderate/marked 0.914 0.119-7.011 n/a n/a
Stromal atypia 0.680 n/a
    Mild vs. moderate/marked 0.639 0.076-5.372 n/a n/a
Stromal mitosis 0.108 n/a
    0-4/10 HPFs vs. ≥ 5/10 HPFs 8.063 0.631-103.0 n/a n/a
Stromal overgrowth 0.041 n/a
    Absent vs. present 4.008 1.059-15.16 n/a n/a
Tumor margin 0.360 n/a
    Circumscribed vs. infiltrative 0.549 0.152-1.985 n/a n/a
YAP (S) 0.050 0.799
    Negative vs. Positive 3.206 1.000-10.27 1.314 0.161-10.733
pYAP (S) 0.661 0.110
    Negative vs. Positive 1.309 0.393-4.364 4.708 0.704-31.48
HPFs, high-power fields.
cytoplasmic YAP expression of epithelial com-
ponent was associated with increased stromal 
cellularity (P = 0.030).
Impact of the expression of YAP and pYAP on 
patient prognosis
According to the above results, we could find 
that YAP and pYAP expressions of stromal com-
ponent were related to higher histologic grade 
and histologic features which were suggested 
with malignancy of PT. Therefore, we deter-
mined to clarify the association of YAP and 
pYAP expression and patient’s prognosis of PT 
(Table 3). First, we produced Kaplan-Meier sur-
vival curves according to YAP and pYAP expres-
sion status by tumor components (Figure 3). As 
expected, patient with PTs which demonstrated 
increased level of YAP expression in the stromal 
component had shorter disease-free survival 
YAP in phyllodes tumor
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(DFS, P < 0.001, Figure 3A) and overall survival 
(OS, P = 0.051, Figure 3B). In like manner, 
patient with PTs which demonstrated increased 
level of pYAP expression in the stromal compo-
nent had shorter DFS (P = 0.042, Figure 3C) 
and OS (P = 0.001, Figure 3D). When we ana-
lyzed patients’ survival according to the histo-
logic grade of PT, YAP expression of the stromal 
component was related to decreased DFS in 
borderline PT (P = 0.029, Figure 3E). Next, we 
analyzed statistical correlation of YAP with sev-
eral predictable variables and patients’ survival 
of PTs using multivariate Cox regression (Table 
4). As a result, only stromal overgrowth demon-
strated about fourfold increase of hazard ratio 
in patient’s DFS (hazard ratio: 4.008, 95% CI: 
1.059-15.16, P = 0.041). Interestingly, stromal 
YAP expression was independently associated 
with increased DFS (Hazard ration: 3.206, 95% 
CI: 1.000-10.27, P = 0.050).
Discussion
YAP is a recently identified oncogenic transcrip-
tion coactivator [15]. As a causative oncogene 
found in 11q22 amplicon frequently observed 
in human cancer, YAP enhances invasion and 
proliferation, suppresses apoptosis and is suf-
ficient for transformation [16]. Hippo pathway 
consists of a kinase cascade including Lats 
kinase, the mammalian homolog of Warts [17], 
and YAP is phosphorylated by Lats kinase to be 
sequestered from the nucleus by 14-3-3 [5]. 
However, the functions of YAP had remained 
very poorly understood until the discovery of 
the Hippo tumor suppressor pathway.
Although PT which belongs to fibroepithelial 
tumor of breast has a malignant potential, 
there is no standard immunohistochemical 
panel helping to predict of biologic behavior of 
PT. Previous reports demonstrated increased 
level of YAP expression in lobular carcinoma 
[13] and the relation of YAP expression and ER/
PR status in breast cancer [14]. In mesenchy-
mal origins, YAP expression of tumor cells in 
osteosarcoma [18], Ewing sarcoma [19], and 
undifferentiated pleomorphic sarcoma [20] 
have been studied. In this study, we assessed 
expression profiles of YAP and pYAP in benign, 
borderline, and malignant PTs according to 
their epithelial and stromal components.
Interestingly, we could find that stromal expres-
sions of YAP and pYAP were increased in bor-
derline and malignant PTs with comparison of 
benign PT along with other malignant mesen-
chymal tumors. As well, YAP expression in the 
stromal component was associated with 
increased stromal cellularity, increased stromal 
atypia, increased stromal mitosis, stromal over-
growth, and infiltrative tumor margin, which 
have been known as histologic features of 
malignant PT. This result is compatible with the 
previous reports about malignant mesenchy-
mal tumors of which YAP expression were asso-
ciated with tumor progression, tumor growth, 
and tumor staging [18-20]. 
We thought that the above results suggested 
the stromal overexpression of YAP and pYAP 
might be associated with patient’s prognosis 
because tumor aggressiveness is determined 
by the histologic features of stromal compo-
nent in PT. As expected, we could determine 
that YAP expression in stromal component was 
related to the poor prognosis. Other research-
ers also found the correlation of YAP expres-
sion and poor prognosis in various epithelial 
tumors: ovarian cancer [6], urinary bladder can-
cer [7], colorectal cancer [8], esophageal can-
cer [9], stomach cancer [10], and lung cancer 
[11]. The excitement of this study was that stro-
mal YAP expression in borderline PTs was relat-
ed to shorter DFS and this suggested the pos-
sibility of YAP protein as a prognosis predictor 
for borderline PT. 
Conventional treatment of choice for PTs is a 
surgical resection. In consideration of target 
therapy, it is needed to develop methods of 
inactivation of YAP protein which might be more 
frequently expression in borderline and malig-
nant PTs than in benign PT. Experimental stud-
ies proposed the suggestions by presenting the 
decrease of cancer cell migration and prolifera-
tion in vitro [21, 22] and the inhibition of tumor 
growth in vivo [21] by YAP inactivation. 
We believe that this study is the first to reveal 
the expression profiles of YAP and pYAP in PTs 
according to their histologic grades and cellular 
components. Furthermore, we could find the 
clinical implication of YAP and pYAP expres-
sions in PT as an indicator of tumor progression 
and a poor prognostic marker.
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